InnoCare Pharma’s ICP-189 First Dosed in China SHP2 Inhibitor Trial
Beijing InnoCare Pharma (HKG: 9969) has announced the first patient dosing in a clinical study...
Fineline Cube
China NT Pharma Group Inks Licensing Deal for Orticumab in Asia
China-based China NT Pharma Group Company Ltd (HKG: 1011) has announced a licensing agreement with...
Mega Genomics Limited Makes Hong Kong IPO Debut at HKD 18 Per Share
China-based gene testing platform company Mega Genomics Limited has successfully completed an initial public offering...
Venus Medtech’s VenusP-Valve Used Compassionately in US for Pulmonary Regurgitation
Venus Medtech (Hangzhou) Inc. (HKG: 2500) announced the first compassionate use of its VenusP-Valve, a...
Merck KGaA’s Erbitux Approved in China for Head and Neck Cancer Treatment
Germany-based pharmaceutical firm Merck KGaA announced that China’s National Medical Products Administration (NMPA) has issued...
CSPC’s JMT103 Accepted for Review in China, Targets RANKL-Related Deficiencies
The Center for Drug Evaluation (CDE) website indicates that a market filing by China-based CSPC...
Grand Pharma Launches SIR-Spheres for Liver Cancer Treatment in China
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced the official launch of its SIR-Spheres...
Beijing Introduces White List System for Biomedical R&D Item Imports
Beijing has announced the introduction of a ‘white list’ system to facilitate the import of...
Ocumension Therapeutics’ OT-401 Approved for Chronic Non-Infectious Uveitis in China
China-based Ocumension Therapeutics (HKG: 1477) has received approval from the National Medical Products Administration (NMPA)...
AstraZeneca Expands in China with Qingdao Partnership and Manufacturing Base
UK-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) is significantly expanding its presence in China through a...
CStone Pharmaceuticals’ Ayvakit Included in Taiwan’s National Health Insurance
China-based CStone Pharmaceuticals (HKG: 2616) announced that its Ayvakit (avapritinib), a tyrosine kinase inhibitor for...
Eureka Biotechnology Secures RMB 100 Million for Cell and Gene Therapy Solutions
Shenzhen-based Eureka Biotechnology, a company specializing in comprehensive solutions for the cell and gene therapy...
Therorna Secures Over RMB 280 Million in Series A Round to Accelerate circRNA Tech Development
China-based Therorna Inc., a biotech company specializing in cutting-edge circular RNA (circRNA) technology for next-generation...
Qingdao HuaRen Pharmaceutical Gains CE Marks for Monkeypox and COVID-19 Detection Kits
China-based Qingdao HuaRen Pharmaceutical Co., Ltd (SHE: 300110) has announced receiving CE marks in the...
SSY Group’s Blonanserin and Paracetamol Approved by China’s NMPA
China-based SSY Group Limited (HKG: 2005) has announced receiving market approvals from the National Medical...
Shanghai ShineYo Medical Device Secures RMB 100 Million in Series A Round
Shanghai ShineYo Medical Device Co., Ltd, a company specializing in electrophysiology and peripheral intervention, has...
Boehringer Ingelheim Venture Fund and Hong Kong Science Park Launch Co-Incubation Plan
Germany-based pharmaceutical giant Boehringer Ingelheim’s venture fund (BIVF) and China-based Hong Kong Science & Technology...
Innovent Biologics’ Tyvyt Approved for First-Line Esophageal Squamous Cell Carcinoma
The National Medical Products Administration (NMPA) website indicates that China-based Innovent Biologics, Inc. (HKG: 1801)...
China’s Seventh National Volume-based Procurement Round Kicks Off with Revised Rules
China’s health authorities have resumed the seventh national volume-based procurement (VBP) round after a pandemic-related...
Shenzhen AXBio Closes USD 100 Million Series B Round for Sequencing Tech Expansion
Shenzhen-based fourth-generation sequencing company Anxuyuan Biotechnology (shenzhen) Company Limited (AXBio) has reportedly secured close to...